# US 2021/0171582 A1 · Method for robust control of gene expression

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171582 A1
- Document ID: US20210171582A1
- Status: Published application
- Kind: A1
- Application number: 17/100,857
- Filed: 2020-11-21
- Published: 2021-06-10
- Earliest claimed: 2019-11-22
- Assignees: California Institute of Technology
- Applicants: California Institute of Technology
- Inventors: Michael J. Flynn; Michael B. Elowitz; Acacia Hori; Viviana Gradinaru
- Web page: https://patentgrep.com/patent/US20210171582A1

## CPC

- C07K 14/005: from viruses
- C07K 14/4702: {Regulators; Modulating activity}
- C12N 9/506: {derived from RNA viruses}
- C12N 15/86: Viral vectors
- C12Y 304/22044: Nuclear-inclusion-a endopeptidase (3.4.22.44)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/60: containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
- C07K 2319/71: containing domain for transcriptional activaation, e.g. VP16
- C07K 2319/95: containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2770/34022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Disclosed herein include methods, compositions, and kits suitable for robust and tunable control of payload gene expression. Some embodiments provide rationally designed circuits, including miRNA-level and/or protein-level incoherent feed-forward loop circuits, that maintain the expression of a payload at an efficacious level. The circuit can comprise a promoter operably linked to a polynucleotide encoding a fusion protein comprising a payload protein, a protease, and one or more self-cleaving peptide sequences. The payload protein can comprise a degron and a cut site the protease is capable of cutting to expose the degron. The circuit can comprise a promoter operably linked to a polynucleotide comprising a payload gene, a silencer effector cassette, and one or more silencer effector binding sequences.

## Claims

### Claim 1

A nucleic acid comprising:
a promoter operably linked to a polynucleotide encoding a fusion protein comprising a payload protein, a protease, and one or more self-cleaving peptide sequences,
wherein the payload protein comprises a degron and a cut site the protease is capable of cutting to expose the degron, and wherein the degron of the payload protein being exposed changes the payload protein to a payload protein destabilized state.

### Claim 2 (depends on 1)

The nucleic acid of claim 1, wherein the degron comprises an N-degron.

### Claim 3 (depends on 1)

The nucleic acid of claim 1, wherein the self-cleaving peptide sequence comprises porcine teschovirus-1 2A peptide (P2A), Thosea asigna virus 2A peptide (T2A), equine rhinitis A virus 2A peptide (E2A), foot-and-mouth disease virus 2A peptide (F2A), or any combination thereof.

### Claim 4 (depends on 1)

The nucleic acid of claim 1, wherein the protease comprises tobacco etch virus (TEV) protease, tobacco vein mottling virus (TVMV) protease, hepatitis C virus protease (HCVP), derivatives thereof, or any combination thereof.

### Claim at position 5

-19. (canceled)

### Claim 20 (depends on 1)

The nucleic acid of claim 1, wherein one or more cells comprise an endogenous version of a gene encoding the payload protein comprising one or more secondary silencer binding sequences in the 3′UTR, wherein the nucleic acid comprises a secondary silencer effector cassette encoding a secondary silencer effector that is capable of binding the one or more secondary silencer binding sequences.

### Claim 21 (depends on 1)

The nucleic acid of claim 1, wherein the polynucleotide further comprises a transcript stabilization element, and wherein the transcript stabilization element comprises woodchuck hepatitis post-translational regulatory element (WPRE), bovine growth hormone polyadenylation (bGH-polyA) signal sequence, human growth hormone polyadenylation (hGH-polyA) signal sequence, or any combination thereof.

### Claim 22 (depends on 1)

The nucleic acid of claim 1, wherein the promoter comprises a ubiquitous promoter, and wherein the ubiquitous promoter is selected from the group comprising a cytomegalovirus (CMV) immediate early promoter, a CMV promoter, a viral simian virus 40 (SV40) (e.g., early or late), a Moloney murine leukemia virus (MoMLV) LTR promoter, a Rous sarcoma virus (RSV) LTR, an RSV promoter, a herpes simplex virus (HSV) (thymidine kinase) promoter, H5, P7.5, and P11 promoters from vaccinia virus, an elongation factor 1-alpha (EF1a) promoter, early growth response 1 (EGR1), ferritin H (FerH), ferritin L (FerL), Glyceraldehyde 3-phosphate dehydrogenase (GAPDH), eukaryotic translation initiation factor 4A1 (EIF4A1), heat shock 70 kDa protein 5 (HSPA5), heat shock protein 90 kDa beta, member 1 (HSP90B1), heat shock protein 70 kDa (HSP70), β-kinesin (β-KIN), the human ROSA 26 locus, a Ubiquitin C promoter (UBC), a phosphoglycerate kinase-1 (PGK) promoter, 3-phosphoglycerate kinase promoter, a cytomegalovirus enhancer, human β-actin (HBA) promoter, chicken β-actin (CBA) promoter, a CAG promoter, a CBH promoter, or any combination thereof.

### Claim 23 (depends on 1)

The nucleic acid of claim 1, wherein the promoter is an inducible promoter, wherein the inducible promoter is a tetracycline responsive promoter, a TRE promoter, a Tre3G promoter, an ecdysone responsive promoter, a cumate responsive promoter, a glucocorticoid responsive promoter, and estrogen responsive promoter, a PPAR-γ promoter, an RU-486 responsive promoter, or any combination thereof.

### Claim 24

(canceled)

### Claim 25 (depends on 1)

The nucleic acid of claim 1, wherein the promoter comprises a tissue-specific promoter, wherein the tissue specific promoter is a liver-specific thyroxin binding globulin (TBG) promoter, an insulin promoter, a glucagon promoter, a somatostatin promoter, a pancreatic polypeptide (PPY) promoter, a synapsin-1 (Syn) promoter, a creatine kinase (MCK) promoter, a mammalian desmin (DES) promoter, a α-myosin heavy chain (a-MHC) promoter, a cardiac Troponin T (cTnT) promoter, or any combination thereof.

### Claim 26 (depends on 1)

The nucleic acid of claim 1, wherein the promoter comprises a tissue-specific promoter, wherein the tissue specific promoter is a neuron-specific promoter, wherein the neuron-specific promoter comprises a synapsin-1 (Syn) promoter, a CaMKIIa promoter, a calcium/calmodulin-dependent protein kinase II a promoter, a tubulin alpha I promoter, a neuron-specific enolase promoter, a platelet-derived growth factor beta chain promoter, TRPV1 promoter, a Nav1.7 promoter, a Nav1.8 promoter, a Nav1.9 promoter, an Advillin promoter, or any combination thereof.

### Claim 27

(canceled)

### Claim 28 (depends on 1)

The nucleic acid of claim 1, wherein the promoter comprises an intronic sequence, a bidirectional promoter and/or an enhancer.

### Claim 29

(canceled)

### Claim 30

(canceled)

### Claim 31 (depends on 1)

The nucleic acid of claim 1, wherein one or more cells comprise an endogenous version of the payload gene, and wherein the promoter comprises or is derived from the promoter of the endogenous version.

### Claim 32 (depends on 1)

The nucleic acid of claim 1, wherein the payload protein comprises a disease-associated protein, wherein aberrant expression of the disease-associated protein correlates with the occurrence and/or progression of the disease.

### Claim 33 (depends on 1)

The nucleic acid of claim 1, wherein the payload protein comprises methyl CpG binding protein 2 (MeCP2), DRK1A, KAT6A, NIPBL, HDAC4, UBE3A, EHMT1, one or more genes encoded on chromosome 9q34.3, NPHP1, LIMK1 one or more genes encoded on chromosome 7q11.23, P53, TPI1, FGFR1 and related genes, RA1, SHANK3, CLN3, NF-1, TP53, PFK, CD40L, CYP19A1, PGRN, CHRNA7, PMP22, CD40LG, derivatives thereof, or any combination thereof.

### Claim 34

(canceled)

### Claim 35

(canceled)

### Claim 36 (depends on 1)

The nucleic acid of claim 1, wherein the payload protein comprises a programmable nuclease, a diagnostic agent, a chimeric antigen receptor, a CRE recombinase, GCaMP, a cell therapy component, a knock-down gene therapy component, a cell-surface exposed epitope, or any combination thereof.

### Claim at position 23

-45. (canceled)

### Claim 46 (depends on 1)

A composition comprising the nucleic acid of claim 1, wherein the composition is a vector, a ribonucleoprotein (RNP) complex, a liposome, a nanoparticle, an exosome, a microvesicle, or any combination thereof.

### Claim 47

(canceled)

### Claim 48

(canceled)

### Claim 49 (depends on 46)

The composition of claim 46, wherein the vector is a viral vector, a plasmid, a naked DNA vector, a lipid nanoparticle, or any combination thereof.

### Claim 50

(canceled)

### Claim 51

(canceled)

### Claim 52 (depends on 46)

A method of treating a disease or disorder in a subject, the method comprising:
introducing into one or more cells of a subject in need thereof the composition of claim 46.

### Claim at position 31

-67. (canceled)

### Claim 68 (depends on 52)

The method of claim 52, wherein, in the absence of the protease and/or the silencer effector, the payload protein reaches untuned steady state payload protein levels in the one or more cells, wherein untuned steady state payload protein levels range between a lower untuned threshold and an upper untuned threshold of an untuned expression range, wherein, in the presence the protease and/or the silencer effector, the payload protein reaches tuned steady state payload protein levels in the one or more cells, wherein tuned steady state payload protein levels range between a lower tuned threshold and an upper tuned threshold of a tuned expression range, wherein the difference between the lower untuned threshold and the upper untuned threshold of the untuned expression range is greater than about two orders of magnitude, and wherein the difference between the lower tuned threshold and the upper tuned threshold of the tuned expression range is less than about one order of magnitude.

### Claim at position 33

-76. (canceled)

### Claim 77 (depends on 68)

The method of any one of claim 68, wherein the lower tuned threshold and/or the upper tuned threshold of a tuned expression range can be increased by introducing one or more non-canonical amino acid substitutions into the cut site, and wherein the lower tuned threshold and/or the upper tuned threshold of a tuned expression range can be reduced by introducing one or more canonical amino acid substitutions into the cut site.

### Claim at position 35

-92. (canceled)
